Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | APLNR | P35414 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30558180 | 0.91 | ITGB3 (0.42) | MEN1TP53CYP1A2CYP2D6MAPT | |
| SCHEMBL10396256 | 0.88 | MEN1 (0.49) | MEN1TP53CYP1A2CYP2D6MAPT | |
| SCHEMBL29409428 | 0.86 | OPRK1 (0.49) | MEN1TP53CYP1A2CYP2D6MAPT | |
| SCHEMBL30817477 | 0.84 | ACE (0.49) | ACE | |
| SCHEMBL30423512 | 0.84 | ACE (0.49) | ACE | |
| SCHEMBL30490568 | 0.84 | ACE (0.43) | ACE | |
| SCHEMBL29609766 | 0.84 | ACE (0.51) | ACE | |
| SCHEMBL30485831 | 0.83 | ACE (0.43) | MAPTACE | |
| SCHEMBL29666810 | 0.82 | ACE (0.43) | MAPTACE | |
| SCHEMBL30138997 | 0.81 | ACE (0.42) | MAPTACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240041740-A1 | SKIN PEEL COMPOSITIONS | GLO PHARMA INC (US) | 2024-02-08 | — | — | US | disclosed |
| US-20230270635-A1 | METHODS AND COMPOSITIONS FOR COSMETIC APPLICATIONS | GLO PHARMA INC (US) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270635-A1 | METHODS AND COMPOSITIONS FOR COSMETIC APPLICATIONS | CUTA, GLA, LIPA | MEN1 1376/4885TP53 763/4885CYP1A2 4581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.